前列腺癌质子束放疗后患者报告与研究者报告CTCAE的一致性评估
本研究在前列腺癌质子束放疗前瞻性临床试验中,用PRO-CTCAE评估急性不良事件并与研究者报告的IR-CTCAE进行一致性分析。55例患者纳入分析,结果显示两者一致性低,医生在治疗结束时低估了泌尿症状和腹泻的频率与严重程度,研究鼓励继续使用患者报告结局。
要点
- 质子束放疗前列腺癌中IR-CTCAE与PRO-CTCAE一致性低。
- 治疗结束时医生低估腹泻和泌尿疼痛的发生率与严重程度。
- 日常活动干扰程度被研究者持续高估(45%-85%)。
核心结论
- 在前列腺癌质子治疗背景下,IR-CTCAE与PRO-CTCAE之间一致性低。
- 与患者报告结局相比,医生在治疗结束时低估了泌尿症状和腹泻的频率与严重程度。
- 应强烈鼓励继续使用患者报告结局(PROs)。
研究设计与样本
- 前瞻性临床试验中,对高危或不利中危前列腺癌患者行质子束放疗。
- 使用11个PRO-CTCAE问题评估胃肠道、泌尿生殖或勃起功能副作用。
- PRO-CTCAE与IR-CTCAE的相关性方案由两名医生独立制定。
- 采用描述性术语和转换后的分级评分分析,用Kappa统计量描述一致性程度。
- 共纳入55例患者。
主要发现
- 治疗结束时IR-CTCAE低估腹泻,低估率为28%(其中11%低估≥2个毒性等级)。
- 治疗结束时泌尿 tract 疼痛被低估45%(其中17%低估≥2个等级)。
- 基线和放疗后3个月差异较不明显。
- 尿急和尿频在治疗前倾向于被高估(分别为36%和24%),但在治疗结束时被低估(分别为35%和31%)。
- 日常活动干扰程度被研究者持续高估(45%-85%);勃起功能障碍不一致率≥2个毒性等级为36%-56%。
临床怎么用
- 在前列腺癌质子放疗中应重视患者报告结局(PROs)的持续使用。
- 医生应警惕对治疗结束时泌尿症状和腹泻的低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report acute patient-reported outcomes using CTCAE (PRO-CTCAE) of proton beam radiotherapy for high-risk or unfavorable intermediate-risk prostate cancer in a prospective clinical trial. PRO-CTCAE were correlated with investigator reported-CTCAE (IR-CTCAE) to assess the degree of concordance. METHODS AND MATERIALS: 11 PRO-CTCAE questions assessed gastrointestinal (GI), genitourinary (GU), or erectile function side effects. The correlation scheme between PRO-CTCAE and IR-CTCAE was independently developed by two physicians. Analyses of PRO-CTCAE and IR-CTCAE were conducted using both descriptive terms and the converted grade scores. The Kappa statistic described the degree of concordance. RESULTS: 55 patients were included. IR-CTCAE underestimated diarrhea compared to PRO-CTCAE at the end of treatment (EOT), with a 28% rate of underestimation (11% by ≥ 2 toxicity grades). Similarly, urinary tract pain was underestimated in 45% of cases (17% by ≥ 2 grades) at EOT. Differences were less pronounced at baseline or 3 months after radiotherapy. The incidence of urinary urgency and frequency tended to be overestimated prior to treatment (36% and 24%, respectively) but underestimated at EOT (35% and 31%, respectively). The degree of interference with daily activities was consistently overestimated by investigators (45%-85%). Finally, erectile dysfunction showed a 36-56% rate of discordance by ≥ 2 toxicity grades. CONCLUSIONS: Our study shows a low agreement between IR-CTCAE and PRO-CTCAE in the setting of proton therapy for prostate cancer. Compared to patient-reported outcomes, physicians underestimated the frequency and severity of urinary symptoms and diarrhea at the end of treatment. Continued use of PROs should be strongly encouraged.
引用
- Kowalchuk RO, Hillman D, Daniels TB, et al. Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. Clin Transl Radiat Oncol. 2021. PMID: 34604551. doi:10.1016/j.ctro.2021.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。